Neurobiological Tech (NTII) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiological Tech (NTII)

NTII 0.0001000

0.0%

Mar 7 3:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Dr. John M. de Castro who wrote (206)	12/17/1997 12:44:00 PM
From: Howard Frederick	Read Replies (1) of 1494

// There has been no announcement of delisting. The stock is getting hammered for no apparent reason. IMO, it is a combination of tax loss selling and a fear of delisting. However, lost in the shuffle is the fact that NTII will have results from the Phase II neuropathic pain trial in January. If these results are positive, and I'm very optimistic // My take is that the stock is getting hammered primarily because of fears it may no longer be a going concern. The results of the above metioned Phase II trial cannot be overstated. If the results are good enough to cause optimism about Memantine and a favorable partnership, you can get multiples on your money at these levels. If the results are inconclusive or poor, you may only get a fraction of these levels back. NTII would almost certainly no longer be in business, the only question being what it would be sold for. Delisting would be the least of your problems. I still own some stock in NTII, and sincerely hope the trial shows good results. Also considering picking up more at these levels. Regardless, this stock is a huge gamble.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next